NCT00236457 – Randomized, Multi-center, Open Label Trial Comparing Risperidone Depot (Microspheres) and Olanzapine Tablets in Patients With Schizophrenia or Schizoaffective Disorder Posted on March 18, 2019 by tsuperadmin -
NCT01855074 – Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone Posted on March 18, 2019 by tsuperadmin -
NCT00495118 – Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder – an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85 Posted on March 18, 2019 by tsuperadmin -
NCT00236353 – An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder Posted on March 18, 2019 by tsuperadmin -
NCT00992407 – A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder Posted on March 18, 2019 by tsuperadmin -
NCT00269919 – Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia Posted on March 18, 2019 by tsuperadmin -
NCT00216528 – A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta) Posted on March 18, 2019 by tsuperadmin -
NCT00086112 – A Double-blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy Posted on December 20, 2018 by tsuperadmin -
NCT01050582 – Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs Posted on December 20, 2018 by tsuperadmin -
NCT00576732 – Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety Posted on December 20, 2018 by tsuperadmin -
The YODA Project